VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 135, Issue 5, Pages 1247-1256
Publisher
Wiley
Online
2014-02-08
DOI
10.1002/ijc.28772
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
- (2013) M Scartozzi et al. BRITISH JOURNAL OF CANCER
- Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
- (2013) Jun Cai et al. World Journal of Surgical Oncology
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2012) Bassam Estfan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
- (2012) Giovan Giuseppe Di Costanzo et al. DIGESTIVE AND LIVER DISEASE
- The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease
- (2012) Hebah H. Al-Habboubi et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients
- (2012) Mario Scartozzi et al. PLoS One
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
- (2011) Koji Miyahara et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Genetics of VEGF Serum Variation in Human Isolated Populations of Cilento: Importance of VEGF Polymorphisms
- (2011) Daniela Ruggiero et al. PLoS One
- Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options
- (2010) Luca Faloppi et al. CANCER TREATMENT REVIEWS
- The changing pattern of epidemiology in hepatocellular carcinoma
- (2010) Helena Nordenstedt et al. DIGESTIVE AND LIVER DISEASE
- The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer
- (2010) K.D. Steffensen et al. GYNECOLOGIC ONCOLOGY
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer
- (2010) T F Hansen et al. PHARMACOGENOMICS JOURNAL
- VEGF −460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma
- (2010) M-H Chen et al. PHARMACOGENOMICS JOURNAL
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer
- (2010) Torben Frøstrup Hansen et al. VIRCHOWS ARCHIV
- Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors
- (2010) Susan A. J. Vaziri et al. Current Oncology Reports
- Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
- (2009) R. C. Kane et al. ONCOLOGIST
- Influence of theVEGF-A936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer
- (2009) Jean-Louis Formento et al. PHARMACOGENOMICS
- Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population
- (2008) Thomas Yau et al. CANCER
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- (2008) A. M. Schultheis et al. CLINICAL CANCER RESEARCH
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet’s disease
- (2008) M. Kamoun et al. TISSUE ANTIGENS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now